Abstract
In treatment-naive patients with Crohn disease, early treatment with a combination of a tumor necrosis factor (TNF) blocker and an antimetabolite (azathioprine, 6-mercaptopurine, or methotrexate), or early combined immunosuppression (ECI), is recognized to result in the highest remission rates. In an industry-funded, cluster-randomized study of community practices, investigators tested the efficacy of ECI versus conventional step-up management. The primary outcome was the rate of steroid-free remission at month 12. Patients were followed for 24 months. In ECI-randomized practices, after initial mandated steroid trials (4 weeks in …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
